Last 12 months
Inside the activity.
0 purchase rows · 1 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 1 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 25, 2023 Filed Sep 27, 2023 23:31 UTC |
ROBERTSON MICHELLEEVP, Chief Financial Officer
|
GrantEmployee Stock Option (right to buy) · Derivative | 1,350,000 | $0.00 Strike: $2.17 | $0.00 |
DisclosureSEC source: 0001062993-23-018539 · form4.xml · derivative · entry 1 ROBERTSON MICHELLE · CIK 0001755098 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,350,000 Underlying: Common Stock · 1,350,000 shares Expires 2033-09-24 F1 · derivative.exercise_date: This option vests as follows:168,750 shares on March 25, 2024, the remaining 1,181,250 shares in a series of 42 equal monthly installments commencing March 25, 2024, provided the optionee continues to provide services to the Company. Read SEC document |
| August 24, 2023 Filed Aug 25, 2023 00:52 UTC |
O'Farrell Elizabeth G.Director
|
PurchaseCommon Stock | 6,579 | $2.28 | $15,000.12 |
DisclosureSEC source: 0001062993-23-017095 · form4.xml · nonDerivative · entry 2 O'Farrell Elizabeth G. · CIK 0001744662 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Spouse Disclosed balance after: 26,220 Read SEC document |
| August 24, 2023 Filed Aug 25, 2023 00:52 UTC |
O'Farrell Elizabeth G.Director
|
PurchaseCommon Stock | 6,607 | $2.28 | $15,063.96 |
DisclosureSEC source: 0001062993-23-017095 · form4.xml · nonDerivative · entry 1 O'Farrell Elizabeth G. · CIK 0001744662 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,407 Read SEC document |
| August 15, 2023 Filed Sep 22, 2023 00:32 UTC |
SCARLETT JOHN ADirector · Chairman, President and CEO
|
GrantEmployee Stock Option (Right to buy) · Derivative | 500,000 | $0.00 Strike: $1.72 | $0.00 |
DisclosureSEC source: 0001062993-23-018393 · form4.xml · derivative · entry 1 SCARLETT JOHN A · CIK 0001270928 · Director · Chairman, President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 500,000 Underlying: Common Stock · 500,000 shares Expires 2028-11-06 F1 · date: Performance-based stock option granted on November 7, 2018 and vested in full on August 15, 2023 upon acceptance of the NDA by the US FDA for imetelstat in lower risk MDS. F1 · derivative.exercise_date: Performance-based stock option granted on November 7, 2018 and vested in full on August 15, 2023 upon acceptance of the NDA by the US FDA for imetelstat in lower risk MDS. Read SEC document |
| August 15, 2023 Filed Sep 22, 2023 00:32 UTC |
GRETHLEIN ANDREW JEVP, Chief Operating Officer
|
GrantEmployee Stock Option (right to buy) · Derivative | 221,544 | $0.00 Strike: $1.72 | $0.00 |
DisclosureSEC source: 0001062993-23-018392 · form4.xml · derivative · entry 1 GRETHLEIN ANDREW J · CIK 0001270921 · EVP, Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 221,544 Underlying: Common Stock · 221,544 shares Expires 2028-11-06 F1 · date: Performance-based stock option granted on November 7, 2018 and vested in full on August 15, 2023 upon acceptance of the NDA by the US FDA for imetelstat in lower risk MDS. F1 · derivative.exercise_date: Performance-based stock option granted on November 7, 2018 and vested in full on August 15, 2023 upon acceptance of the NDA by the US FDA for imetelstat in lower risk MDS. Read SEC document |
| August 15, 2023 Filed Sep 22, 2023 00:31 UTC |
Feller FayeEVP, Chief Medical Officer
|
GrantEmployee Stock Option (right to buy) · Derivative | 180,000 | $0.00 Strike: $1.93 | $0.00 |
DisclosureSEC source: 0001062993-23-018391 · form4.xml · derivative · entry 2 Feller Faye · CIK 0001937361 · EVP, Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 180,000 Underlying: Common Stock · 180,000 shares Expires 2032-07-07 F2 · date: Performance-based stock option granted on July 8, 2022 and vested in full on August 15, 2023 upon acceptance of the NDA by the US FDA for imetelstat in lower risk MDS. F2 · derivative.exercise_date: Performance-based stock option granted on July 8, 2022 and vested in full on August 15, 2023 upon acceptance of the NDA by the US FDA for imetelstat in lower risk MDS. Read SEC document |
| August 15, 2023 Filed Sep 22, 2023 00:31 UTC |
Feller FayeEVP, Chief Medical Officer
|
GrantEmployee Stock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $1.06 | $0.00 |
DisclosureSEC source: 0001062993-23-018391 · form4.xml · derivative · entry 1 Feller Faye · CIK 0001937361 · EVP, Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2032-02-15 F1 · date: Performance-based stock option granted on February 16, 2022 and vested in full on August 15, 2023 upon acceptance of the NDA by the US FDA for imetelstat in lower risk MDS. F1 · derivative.exercise_date: Performance-based stock option granted on February 16, 2022 and vested in full on August 15, 2023 upon acceptance of the NDA by the US FDA for imetelstat in lower risk MDS. Read SEC document |
| August 15, 2023 Filed Sep 22, 2023 00:31 UTC |
Bloom Olivia KyusukEVP, Chief Financial Officer
|
GrantEmployee Stock Option (right to buy) · Derivative | 250,000 | $0.00 Strike: $1.72 | $0.00 |
DisclosureSEC source: 0001062993-23-018390 · form4.xml · derivative · entry 1 Bloom Olivia Kyusuk · CIK 0001501545 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 250,000 shares Expires 2028-11-06 F1 · date: Performance-based stock option granted on November 7, 2018 and vested in full on August 15, 2023 upon acceptance of the NDA by the US FDA for imetelstat in lower risk MDS. F1 · derivative.exercise_date: Performance-based stock option granted on November 7, 2018 and vested in full on August 15, 2023 upon acceptance of the NDA by the US FDA for imetelstat in lower risk MDS. Read SEC document |
| August 01, 2023 Filed Aug 3, 2023 22:02 UTC |
Samuels Scott AlanEVP, Chief Legal Officer
|
GrantEmployee Stock Option (right to buy) · Derivative | 1,350,000 | $0.00 Strike: $3.21 | $0.00 |
DisclosureSEC source: 0001062993-23-015795 · form4.xml · derivative · entry 1 Samuels Scott Alan · CIK 0001987259 · EVP, Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,350,000 Underlying: Common Stock · 1,350,000 shares Expires 2033-07-31 F1 · derivative.exercise_date: This option vests as follows:168,750 shares on February 1, 2024, the remaining 1,181,250 shares in a series of 42 equal monthly installments commencing February 1, 2024, provided the optionee continues to provide services to the Company. Read SEC document |
| June 30, 2023 Filed Jul 1, 2023 01:19 UTC |
Molineaux SusanDirector
|
GrantCommon Stock | 4,088 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-014272 · form4.xml · nonDerivative · entry 1 Molineaux Susan · CIK 0001553389 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · Family Trust Disclosed balance after: 118,116 F1 · kind: Shares issued in lieu of cash payment for annual board of directors retainer fee. Number of shares issued based on close price of Geron Common stock on June 30, 2023 of $3.21 per share. F1 · price: Shares issued in lieu of cash payment for annual board of directors retainer fee. Number of shares issued based on close price of Geron Common stock on June 30, 2023 of $3.21 per share. Read SEC document |
| June 30, 2023 Filed Jul 1, 2023 01:19 UTC |
Spiegel Robert J.Director
|
GrantCommon Stock | 2,239 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-014271 · form4.xml · nonDerivative · entry 1 Spiegel Robert J. · CIK 0001492256 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 157,244 F1 · kind: Shares issued in lieu of cash payment for quarterly board of directors retainer fee. Number of shares issued based on close price of Geron Common stock on June 30, 2023 of $3.21 per share. F1 · price: Shares issued in lieu of cash payment for quarterly board of directors retainer fee. Number of shares issued based on close price of Geron Common stock on June 30, 2023 of $3.21 per share. Read SEC document |
| June 30, 2023 Filed Jul 1, 2023 01:18 UTC |
Kapur AnilEVP, Corp Strategy & CCO
|
GrantCommon Stock | 7,567 | $2.04 | $15,436.68 |
DisclosureSEC source: 0001062993-23-014270 · form4.xml · nonDerivative · entry 1 Kapur Anil · CIK 0001730703 · EVP, Corp Strategy & CCO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,783 F1 · shares: The reporting person is voluntarily reporting the acquisition of 7,567 shares of the Issuer's common stock pursuant to the Geron Corporation 2014 Employee Stock Purchase Plan ("ESPP") for the ESPP purchase period of January 3, 2023 through June 30, 2023. This transaction is exempt under Rule 16b-3(c). F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the Issuer's common stock on January 3, 2023. F3 · balance_after: The total number of securities beneficially owned of 60,783 shares represents the aggregate number of shares of Geron common stock purchased under the ESPP. Read SEC document |
| May 31, 2023 Filed Jun 3, 2023 00:53 UTC |
Bir Dawn CarterDirector
|
GrantStock Option (right to buy) · Derivative | 125,000 | $0.00 Strike: $3.27 | $0.00 |
DisclosureSEC source: 0001062993-23-012828 · form4.xml · derivative · entry 1 Bir Dawn Carter · CIK 0001688712 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2033-05-30 F1 · derivative.exercise_date: This option will vest and become exercisable as to 100% of the shares of common stock subject to such option on the earlier of (i) the date of the next annual meeting of the Company's stockholders or (ii) the first anniversary of the date of grant of such option, subject to the non-employee director's continuous service with the Company through such dates. Read SEC document |
| May 31, 2023 Filed Jun 2, 2023 23:36 UTC |
Spiegel Robert J.Director
|
GrantStock Option (right to buy) · Derivative | 125,000 | $0.00 Strike: $3.27 | $0.00 |
DisclosureSEC source: 0001062993-23-012823 · form4.xml · derivative · entry 1 Spiegel Robert J. · CIK 0001492256 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2033-05-30 F1 · derivative.exercise_date: This option will vest and become exercisable as to 100% of the shares of common stock subject to such option on the earlier of (i) the date of the next annual meeting of the Company's stockholders or (ii) the first anniversary of the date of grant of such option, subject to the non-employee director's continuous service with the Company through such dates. Read SEC document |
| May 31, 2023 Filed Jun 2, 2023 23:35 UTC |
O'Farrell Elizabeth G.Director
|
GrantStock Option (right to buy) · Derivative | 125,000 | $0.00 Strike: $3.27 | $0.00 |
DisclosureSEC source: 0001062993-23-012821 · form4.xml · derivative · entry 1 O'Farrell Elizabeth G. · CIK 0001744662 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2033-05-30 F1 · derivative.exercise_date: This option will vest and become exercisable as to 100% of the shares of common stock subject to such option on the earlier of (i) the date of the next annual meeting of the Company's stockholders or (ii) the first anniversary of the date of grant of such option, subject to the non-employee director's continuous service with the Company through such dates. Read SEC document |
| May 31, 2023 Filed Jun 2, 2023 23:34 UTC |
Molineaux SusanDirector
|
GrantStock Option (right to buy) · Derivative | 125,000 | $0.00 Strike: $3.27 | $0.00 |
DisclosureSEC source: 0001062993-23-012819 · form4.xml · derivative · entry 1 Molineaux Susan · CIK 0001553389 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2033-05-30 F1 · derivative.exercise_date: This option will vest and become exercisable as to 100% of the shares of common stock subject to such option on the earlier of (i) the date of the next annual meeting of the Company's stockholders or (ii) the first anniversary of the date of grant of such option, subject to the non-employee director's continuous service with the Company through such dates. Read SEC document |
| May 31, 2023 Filed Jun 2, 2023 23:33 UTC |
McDonald John FDirector
|
GrantStock Options (right to buy) · Derivative | 125,000 | $0.00 Strike: $3.27 | $0.00 |
DisclosureSEC source: 0001062993-23-012817 · form4.xml · derivative · entry 1 McDonald John F · CIK 0001944633 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2033-05-30 F1 · derivative.exercise_date: This option will vest and become exercisable as to 100% of the shares of common stock subject to such option on the earlier of (i) the date of the next annual meeting of the Company's stockholders or (ii) the first anniversary of the date of grant of such option, subject to the non-employee director's continuous service with the Company through such dates. Read SEC document |
| May 31, 2023 Filed Jun 2, 2023 23:32 UTC |
LAWLIS V BRYANDirector
|
GrantStock Option (right to buy) · Derivative | 125,000 | $0.00 Strike: $3.27 | $0.00 |
DisclosureSEC source: 0001062993-23-012815 · form4.xml · derivative · entry 1 LAWLIS V BRYAN · CIK 0001247681 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2033-05-30 F1 · derivative.exercise_date: This option will vest and become exercisable as to 100% of the shares of common stock subject to such option on the earlier of (i) the date of the next annual meeting of the Company's stockholders or (ii) the first anniversary of the date of grant of such option, subject to the non-employee director's continuous service with the Company through such dates. Read SEC document |
| May 11, 2023 Filed May 12, 2023 01:01 UTC |
LAWLIS V BRYANDirector
|
Exercise / conversionStock Options (right to buy) · Derivative | 35,000 | $0.00 Strike: $1.10 | $0.00 |
DisclosureSEC source: 0001062993-23-010852 · form4.xml · derivative · entry 3 LAWLIS V BRYAN · CIK 0001247681 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 35,000 shares Expires 2023-05-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: This transaction reflects an exercise and sale of options due to expire on May 22, 2023 and was conducted pursuant to an approved 10b5-1 trading plan adopted by the reporting person on January 6, 2023. F1 · derivative.exercise_date: Option was fully vested. Read SEC document |
| May 11, 2023 Filed May 12, 2023 01:01 UTC |
LAWLIS V BRYANDirector
|
SaleCommon Stock | 35,000 | $3.00 | $105,000.00 |
DisclosureSEC source: 0001062993-23-010852 · form4.xml · nonDerivative · entry 2 LAWLIS V BRYAN · CIK 0001247681 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F2 · kind: This transaction reflects an exercise and sale of options due to expire on May 22, 2023 and was conducted pursuant to an approved 10b5-1 trading plan adopted by the reporting person on January 6, 2023. Read SEC document |
| May 11, 2023 Filed May 12, 2023 01:01 UTC |
LAWLIS V BRYANDirector
|
Exercise / conversionCommon Stock | 35,000 | $1.10 | $38,500.00 |
DisclosureSEC source: 0001062993-23-010852 · form4.xml · nonDerivative · entry 1 LAWLIS V BRYAN · CIK 0001247681 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 35,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: This transaction reflects an exercise and sale of options due to expire on May 22, 2023 and was conducted pursuant to an approved 10b5-1 trading plan adopted by the reporting person on January 6, 2023. Read SEC document |
| May 01, 2023 Filed May 2, 2023 01:20 UTC |
Molineaux SusanDirector
|
Exercise / conversionStock Options (right to buy) · Derivative | 35,000 | $0.00 Strike: $1.10 | $0.00 |
DisclosureSEC source: 0001062993-23-009883 · form4.xml · derivative · entry 3 Molineaux Susan · CIK 0001553389 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 35,000 shares Expires 2023-05-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: This transaction reflects an exercise and sale of options due to expire on May 22, 2023 and was conducted pursuant to an approved 10b5-1 trading plan adopted by the reporting person on February 17, 2023. F1 · derivative.exercise_date: Option was fully vested. Read SEC document |
| May 01, 2023 Filed May 2, 2023 01:20 UTC |
Molineaux SusanDirector
|
SaleCommon Stock | 35,000 | $2.48 | $86,800.00 |
DisclosureSEC source: 0001062993-23-009883 · form4.xml · nonDerivative · entry 2 Molineaux Susan · CIK 0001553389 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F2 · kind: This transaction reflects an exercise and sale of options due to expire on May 22, 2023 and was conducted pursuant to an approved 10b5-1 trading plan adopted by the reporting person on February 17, 2023. Read SEC document |
| May 01, 2023 Filed May 2, 2023 01:20 UTC |
Molineaux SusanDirector
|
Exercise / conversionCommon Stock | 35,000 | $1.10 | $38,500.00 |
DisclosureSEC source: 0001062993-23-009883 · form4.xml · nonDerivative · entry 1 Molineaux Susan · CIK 0001553389 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: This transaction reflects an exercise and sale of options due to expire on May 22, 2023 and was conducted pursuant to an approved 10b5-1 trading plan adopted by the reporting person on February 17, 2023. Read SEC document |
| March 31, 2023 Filed Apr 4, 2023 00:47 UTC |
Molineaux SusanDirector
|
GrantCommon Stock | 6,048 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-008380 · form4.xml · nonDerivative · entry 1 Molineaux Susan · CIK 0001553389 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · Family Trust Disclosed balance after: 114,028 F1 · kind: Shares issued in lieu of cash payment for annual board of directors retainer fee. Number of shares issued based on close price of Geron Common stock on March 31, 2023 of $2.17 per share. F1 · price: Shares issued in lieu of cash payment for annual board of directors retainer fee. Number of shares issued based on close price of Geron Common stock on March 31, 2023 of $2.17 per share. Read SEC document |
| March 31, 2023 Filed Apr 4, 2023 00:46 UTC |
Spiegel Robert J.Director
|
GrantCommon Stock | 3,312 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-008378 · form4.xml · nonDerivative · entry 1 Spiegel Robert J. · CIK 0001492256 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 155,005 F1 · kind: Shares issued in lieu of cash payment for quarterly board of directors retainer fee. Number of shares issued based on close price of Geron Common stock on March 31, 2023 of $2.17 per share. F1 · price: Shares issued in lieu of cash payment for quarterly board of directors retainer fee. Number of shares issued based on close price of Geron Common stock on March 31, 2023 of $2.17 per share. Read SEC document |
| February 22, 2023 Filed Feb 25, 2023 00:18 UTC |
Kapur AnilEVP, Corp Strategy & CCO
|
GrantEmployee Stock Option (right to buy) · Derivative | 625,000 | $0.00 Strike: $2.83 | $0.00 |
DisclosureSEC source: 0001062993-23-004902 · form4.xml · derivative · entry 1 Kapur Anil · CIK 0001730703 · EVP, Corp Strategy & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 625,000 Underlying: Common Stock · 625,000 shares Expires 2033-02-21 F1 · derivative.exercise_date: This option vests in a series of 48 consecutive equal monthly installments commencing February 22, 2023, provided the optionee continues to provide services to the Company. Read SEC document |
| February 22, 2023 Filed Feb 25, 2023 00:18 UTC |
GRETHLEIN ANDREW JEVP, Chief Operating Officer
|
GrantEmployee Stock Option (right to buy) · Derivative | 780,000 | $0.00 Strike: $2.83 | $0.00 |
DisclosureSEC source: 0001062993-23-004901 · form4.xml · derivative · entry 1 GRETHLEIN ANDREW J · CIK 0001270921 · EVP, Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 780,000 Underlying: Common Stock · 780,000 shares Expires 2033-02-21 F1 · derivative.exercise_date: This option vests in a series of 48 consecutive equal monthly installments commencing February 22, 2023, provided the optionee continues to provide services to the Company. Read SEC document |
| February 22, 2023 Filed Feb 25, 2023 00:17 UTC |
Feller FayeEVP, Chief Medical Officer
|
GrantEmployee Stock Option (right to buy) · Derivative | 540,000 | $0.00 Strike: $2.83 | $0.00 |
DisclosureSEC source: 0001062993-23-004900 · form4.xml · derivative · entry 1 Feller Faye · CIK 0001937361 · EVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 540,000 Underlying: Common Stock · 540,000 shares Expires 2033-02-21 F1 · derivative.exercise_date: This option vests in a series of 48 consecutive equal monthly installments commencing February 22, 2023, provided the optionee continues to provide services to the Company. Read SEC document |
| February 22, 2023 Filed Feb 25, 2023 00:17 UTC |
Bloom Olivia KyusukEVP, Chief Financial Officer
|
GrantEmployee Stock Option (right to buy) · Derivative | 575,000 | $0.00 Strike: $2.83 | $0.00 |
DisclosureSEC source: 0001062993-23-004899 · form4.xml · derivative · entry 1 Bloom Olivia Kyusuk · CIK 0001501545 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 575,000 Underlying: Common Stock · 575,000 shares Expires 2033-02-21 F1 · derivative.exercise_date: This option vests in a series of 48 consecutive equal monthly installments commencing February 22, 2023, provided the optionee continues to provide services to the Company. Read SEC document |
| February 22, 2023 Filed Feb 25, 2023 00:16 UTC |
SCARLETT JOHN ADirector · Chairman, President and CEO
|
GrantEmployee Stock Option (Right to buy) · Derivative | 1,750,000 | $0.00 Strike: $2.83 | $0.00 |
DisclosureSEC source: 0001062993-23-004898 · form4.xml · derivative · entry 1 SCARLETT JOHN A · CIK 0001270928 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,750,000 Underlying: Common Stock · 1,750,000 shares Expires 2033-02-21 F1 · derivative.exercise_date: This option vests in a series of 48 consecutive equal monthly installments commencing February 22, 2023, provided the optionee continues to provide service to the Company. Read SEC document |
| February 10, 2023 Filed Feb 11, 2023 02:47 UTC |
SCARLETT JOHN ADirector · Chairman, President and CEO
|
Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 446,668 | $0.00 Strike: $1.50 | $0.00 |
DisclosureSEC source: 0001062993-23-002790 · form4.xml · derivative · entry 9 SCARLETT JOHN A · CIK 0001270928 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 446,668 shares Expires 2023-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: These transactions reflect exercises and sales of options due to expire on February 13, 2023 and were conducted pursuant to an approved 10b5-1 trading plan adopted by the reporting person on January 9, 2023. F1 · derivative.exercise_date: Option was fully vested. Read SEC document |
| February 10, 2023 Filed Feb 11, 2023 02:47 UTC |
SCARLETT JOHN ADirector · Chairman, President and CEO
|
SaleCommon Stock | 446,668 | $3.00 | $1,340,004.00 |
DisclosureSEC source: 0001062993-23-002790 · form4.xml · nonDerivative · entry 6 SCARLETT JOHN A · CIK 0001270928 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F2 · kind: These transactions reflect exercises and sales of options due to expire on February 13, 2023 and were conducted pursuant to an approved 10b5-1 trading plan adopted by the reporting person on January 9, 2023. Read SEC document |
| February 10, 2023 Filed Feb 11, 2023 02:47 UTC |
SCARLETT JOHN ADirector · Chairman, President and CEO
|
Exercise / conversionCommon Stock | 446,668 | $1.50 | $670,002.00 |
DisclosureSEC source: 0001062993-23-002790 · form4.xml · nonDerivative · entry 5 SCARLETT JOHN A · CIK 0001270928 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 446,668 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: These transactions reflect exercises and sales of options due to expire on February 13, 2023 and were conducted pursuant to an approved 10b5-1 trading plan adopted by the reporting person on January 9, 2023. Read SEC document |
| February 09, 2023 Filed Feb 11, 2023 02:49 UTC |
GRETHLEIN ANDREW JEVP, Chief Operating Officer
|
Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 150,000 | $0.00 Strike: $1.51 | $0.00 |
DisclosureSEC source: 0001062993-23-002794 · form4.xml · derivative · entry 4 GRETHLEIN ANDREW J · CIK 0001270921 · EVP, Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 150,000 shares Expires 2023-02-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: This transaction reflects an exercise and sale of options due to expire on February 12, 2023 and was conducted pursuant to an approved 10b5-1 trading plan adopted by the reporting person on January 9, 2023. F1 · derivative.exercise_date: The options were fully vested. Read SEC document |
| February 09, 2023 Filed Feb 11, 2023 02:49 UTC |
GRETHLEIN ANDREW JEVP, Chief Operating Officer
|
SaleCommon Stock | 234,719 | $3.03 | $711,198.57 |
DisclosureSEC source: 0001062993-23-002794 · form4.xml · nonDerivative · entry 3 GRETHLEIN ANDREW J · CIK 0001270921 · EVP, Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F3 · kind: Shares sold to meet tax obligations and pursuant to an approved 10b5-1 trading plan adopted by the reporting person on January 9, 2023. Read SEC document |
| February 09, 2023 Filed Feb 11, 2023 02:49 UTC |
GRETHLEIN ANDREW JEVP, Chief Operating Officer
|
SaleCommon Stock | 150,000 | $3.03 | $454,500.00 |
DisclosureSEC source: 0001062993-23-002794 · form4.xml · nonDerivative · entry 2 GRETHLEIN ANDREW J · CIK 0001270921 · EVP, Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 234,719 F2 · kind: This transaction reflects an exercise and sale of options due to expire on February 12, 2023 and was conducted pursuant to an approved 10b5-1 trading plan adopted by the reporting person on January 9, 2023. Read SEC document |
| February 09, 2023 Filed Feb 11, 2023 02:49 UTC |
GRETHLEIN ANDREW JEVP, Chief Operating Officer
|
Exercise / conversionCommon Stock | 150,000 | $1.51 | $226,500.00 |
DisclosureSEC source: 0001062993-23-002794 · form4.xml · nonDerivative · entry 1 GRETHLEIN ANDREW J · CIK 0001270921 · EVP, Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 384,719 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: This transaction reflects an exercise and sale of options due to expire on February 12, 2023 and was conducted pursuant to an approved 10b5-1 trading plan adopted by the reporting person on January 9, 2023. Read SEC document |
| February 09, 2023 Filed Feb 11, 2023 02:47 UTC |
SCARLETT JOHN ADirector · Chairman, President and CEO
|
Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 446,666 | $0.00 Strike: $1.50 | $0.00 |
DisclosureSEC source: 0001062993-23-002790 · form4.xml · derivative · entry 8 SCARLETT JOHN A · CIK 0001270928 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 446,666 shares Expires 2023-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: These transactions reflect exercises and sales of options due to expire on February 13, 2023 and were conducted pursuant to an approved 10b5-1 trading plan adopted by the reporting person on January 9, 2023. F1 · derivative.exercise_date: Option was fully vested. Read SEC document |
| February 09, 2023 Filed Feb 11, 2023 02:47 UTC |
SCARLETT JOHN ADirector · Chairman, President and CEO
|
SaleCommon Stock | 446,666 | $3.03 | $1,353,397.98 |
DisclosureSEC source: 0001062993-23-002790 · form4.xml · nonDerivative · entry 4 SCARLETT JOHN A · CIK 0001270928 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F2 · kind: These transactions reflect exercises and sales of options due to expire on February 13, 2023 and were conducted pursuant to an approved 10b5-1 trading plan adopted by the reporting person on January 9, 2023. Read SEC document |
| February 09, 2023 Filed Feb 11, 2023 02:47 UTC |
SCARLETT JOHN ADirector · Chairman, President and CEO
|
Exercise / conversionCommon Stock | 446,666 | $1.50 | $669,999.00 |
DisclosureSEC source: 0001062993-23-002790 · form4.xml · nonDerivative · entry 3 SCARLETT JOHN A · CIK 0001270928 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 446,666 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: These transactions reflect exercises and sales of options due to expire on February 13, 2023 and were conducted pursuant to an approved 10b5-1 trading plan adopted by the reporting person on January 9, 2023. Read SEC document |
| February 08, 2023 Filed Feb 11, 2023 02:48 UTC |
Bloom Olivia KyusukEVP, Chief Financial Officer
|
Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 400,000 | $0.00 Strike: $1.51 | $0.00 |
DisclosureSEC source: 0001062993-23-002792 · form4.xml · derivative · entry 3 Bloom Olivia Kyusuk · CIK 0001501545 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 400,000 shares Expires 2023-02-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: This transaction reflects an exercise and sale of options due to expire on February 12, 2023 and was conducted pursuant to an approved 10b5-1 trading plan adopted by the reporting person on January 9, 2023. F1 · derivative.exercise_date: Option was fully vested. Read SEC document |
| February 08, 2023 Filed Feb 11, 2023 02:48 UTC |
Bloom Olivia KyusukEVP, Chief Financial Officer
|
SaleCommon Stock | 400,000 | $3.08 | $1,232,000.00 |
DisclosureSEC source: 0001062993-23-002792 · form4.xml · nonDerivative · entry 2 Bloom Olivia Kyusuk · CIK 0001501545 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,588 F2 · kind: This transaction reflects an exercise and sale of options due to expire on February 12, 2023 and was conducted pursuant to an approved 10b5-1 trading plan adopted by the reporting person on January 9, 2023. Read SEC document |
| February 08, 2023 Filed Feb 11, 2023 02:48 UTC |
Bloom Olivia KyusukEVP, Chief Financial Officer
|
Exercise / conversionCommon Stock | 400,000 | $1.51 | $604,000.00 |
DisclosureSEC source: 0001062993-23-002792 · form4.xml · nonDerivative · entry 1 Bloom Olivia Kyusuk · CIK 0001501545 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 474,588 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: This transaction reflects an exercise and sale of options due to expire on February 12, 2023 and was conducted pursuant to an approved 10b5-1 trading plan adopted by the reporting person on January 9, 2023. Read SEC document |
| February 08, 2023 Filed Feb 11, 2023 02:47 UTC |
SCARLETT JOHN ADirector · Chairman, President and CEO
|
Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 446,666 | $0.00 Strike: $1.50 | $0.00 |
DisclosureSEC source: 0001062993-23-002790 · form4.xml · derivative · entry 7 SCARLETT JOHN A · CIK 0001270928 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 446,666 shares Expires 2023-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: These transactions reflect exercises and sales of options due to expire on February 13, 2023 and were conducted pursuant to an approved 10b5-1 trading plan adopted by the reporting person on January 9, 2023. F1 · derivative.exercise_date: Option was fully vested. Read SEC document |
| February 08, 2023 Filed Feb 11, 2023 02:47 UTC |
SCARLETT JOHN ADirector · Chairman, President and CEO
|
SaleCommon Stock | 446,666 | $3.08 | $1,375,731.28 |
DisclosureSEC source: 0001062993-23-002790 · form4.xml · nonDerivative · entry 2 SCARLETT JOHN A · CIK 0001270928 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F2 · kind: These transactions reflect exercises and sales of options due to expire on February 13, 2023 and were conducted pursuant to an approved 10b5-1 trading plan adopted by the reporting person on January 9, 2023. Read SEC document |
| February 08, 2023 Filed Feb 11, 2023 02:47 UTC |
SCARLETT JOHN ADirector · Chairman, President and CEO
|
Exercise / conversionCommon Stock | 446,666 | $1.50 | $669,999.00 |
DisclosureSEC source: 0001062993-23-002790 · form4.xml · nonDerivative · entry 1 SCARLETT JOHN A · CIK 0001270928 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 446,666 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: These transactions reflect exercises and sales of options due to expire on February 13, 2023 and were conducted pursuant to an approved 10b5-1 trading plan adopted by the reporting person on January 9, 2023. Read SEC document |
| January 13, 2023 Filed Jan 18, 2023 00:01 UTC |
EASTHAM KARINDirector
|
Exercise / conversionStock Options (right to buy) · Derivative | 35,000 | $0.00 Strike: $1.10 | $0.00 |
DisclosureSEC source: 0001062993-23-001007 · form4.xml · derivative · entry 2 EASTHAM KARIN · CIK 0001231845 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 35,000 shares Expires 2023-05-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The options were fully vested. F1 · derivative.exercise_date: The options were fully vested. Read SEC document |
| January 13, 2023 Filed Jan 18, 2023 00:01 UTC |
EASTHAM KARINDirector
|
Exercise / conversionCommon Stock | 35,000 | $1.10 | $38,500.00 |
DisclosureSEC source: 0001062993-23-001007 · form4.xml · nonDerivative · entry 1 EASTHAM KARIN · CIK 0001231845 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,047 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 30, 2022 Filed Jan 4, 2023 01:55 UTC |
Kapur AnilEVP, Corp Strategy & CCO
|
GrantCommon Stock | 6,021 | $1.11 | $6,683.31 |
DisclosureSEC source: 0001062993-23-000093 · form4.xml · nonDerivative · entry 1 Kapur Anil · CIK 0001730703 · EVP, Corp Strategy & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,216 F1 · shares: The reporting person is voluntarily reporting the acquisition of 6,021 shares of the Issuer's common stock pursuant to the Geron Corporation 2014 Employee Stock Purchase Plan ("ESPP") for the ESPP purchase period of July 1, 2022 through December 30, 2022 for the 12 month offering period beginning January 3, 2022. This transaction is exempt under Rule 16b-3(c). F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the Issuer's common stock on January 3, 2022. F3 · balance_after: The total number of securities beneficially owned of 53,216 shares represents the aggregate number of shares of Geron common stock purchased under the ESPP. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.